Skip to main content
Home
  • Global
  • Careers
  • Investors
  • About us
    Fagron company profile

    Activities of Fagron

    Leadership team

    Introduction to members of the Leadership team

    Key figures

    Fagron's key figures in one overview

  • Press
    • Press releases
    • Press kit
  • Publications
    Annual reports

    Please find here our annual reports

    Presentations

    Presentations and conference calls

    Statutory annual accounts

    Please find here the statutory annual accounts

    Prospectus September 2007

    Prospectus of the Initial Public Offering

    Prospectus June 2012

    Prospectus of the 4.75% bond

    Prospectus June 2016

    Prospectus of the capital increase

    Bond

    Compliance certificates and guarantor lists

  • Share
    Share performance

    Look at the actual share performance

    Notification of shareholdings

    Shareholding declaration obligation 

    Dividend

    Dividend policy of Fagron

    Shareholders' meetings

    Documents relating to shareholders' meetings

    Analyst coverage

    Analysts covering Fagron

    Shareholder structure

    Overview of participations

  • Events
    Calendar

    Upcoming events

  • Corporate Governance
    Board of Directors

    Members of the Fagron's Board of Directors

    Leadership team

    Introduction to members of the Leadership team

    Governance documents

    Corporate governance documents

Search form

Go to share performance
  • Shareholders
Back to overview
Print Friendly and PDF
Share by mail

Fagron realizes turnover growth of 10.7% CER

13 October 2020

Regulated information
Nazareth (Belgium)/Rotterdam (The Netherlands), 13 October 2020

Fagron realizes turnover growth of 10.7% CER

Fagron enters Israeli market with acquisition of Pharma Tamar

Highlights Q3-2020

  • Turnover growth1of 10.7% CER2to € 135.1 million
  • Organic turnover growth of 8.2% CER
  • Significant weakening of BRL and MXN against EUR results in reported turnover decline of 0.4%
  • Strong performance, particularly in Latin America; North America also reports good growth in turnover
  • Impact of COVID-19 pandemic remained limited and non-material
  • Acquisition of Pharma Tamar in Israel completed in August
  • CEO Rafael Padilla will directly lead EMEA region; focus on innovation and time-to-market  
  • European organization being structured more efficiently

Rafael Padilla, CEO of Fagron: “As expected the third quarter was also to a large extent defined by the impact of the COVID-19 pandemic, which we were able to navigate well thanks to our product and regional diversification and our reliable supply chain. Both in terms of turnover development and profitability, Fagron once again showed a good performance in the third quarter.

The course and effects of the pandemic vary from region to region. Demand for COVID-19-related products, mainly at the Brands and Essentials segments, is keeping pace with the development in the infection rate, which is rising again in a number of regions. Demand for elective care recovered in a number of regions, although it is being scaled back again in areas where the number of cases is on the rise.

We are able to respond to both of these developments well with our diversified product portfolio, as is evidenced by the performance in Latin America and North America. In the Netherlands, where we traditionally have a strong position in Compounding Services, the impact of scaling back elective care is more difficult to offset by the increase in demand for COVID-19-related products.

The European activities are being structured more efficiently to enable us to respond even quicker in the market. As part of this restructuring I am going to lead the EMEA region (Europe, South Africa and Israel) myself. The flatter organizational structure will lead to better collaboration in order to increase our strength and impact as a market leader and to realize synergies and economies of scale. Furthermore, we will focus more on innovation, the development of Brands and a shorter time-to-market.

Another important development remains consolidation and we are proud to have further strengthened our group in the third quarter of 2020 with the acquisition of Pharma Tamar in Israel. Fagron remains alert to possible acquisition opportunities that may arise in the current market dynamics.

The coming quarter will also be dominated by COVID-19 and visibility is limited. We will continue to pursue our policy aimed at making the most of opportunities while remaining critical of our costs.” 
__________________
1 Excluding HL Technology which was divested in the fourth quarter of 2019.
2 CER = Constant Exchange Rates.

Please open the link below for the press release:
Fagron realizes turnover growth of 10.7% CER

Fagron realizes turnover growth of 10.7% CER
Recording conference call October 13th, 2020

About Fagron

Fagron is the leading global pharmaceutical compounding company, bringing customized pharmaceutical care to hospitals, pharmacies, clinics and patients in 35 countries worldwide.

Press releases

Sign up to receive our latest press releases.

Subscribe

Contact us

  • +31 (0) 88 33 11 200
  • investors@fagron.com

Contact information

© Copyright 2021 Fagron.

  • Disclaimer
  • Privacy Statement